Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

Novo Nordisk has ended its partnership with Hims & Hers Health Inc., citing “deceptive marketing” and the selling of ...

The group is speaking with insurers, urging them to follow the science and hoping to give the companies “a neutral, ...

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Novo Nordisk's best-known drug, Wegovy, targets a GPCR called GLP-1. Eli Lilly 's popular weight-loss drug Zepbound targets both GLP-1 and another GPCR called GIP.

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

A Novo Nordisk challenge to the Medicare price negotiation program is being closely watched Adobe By John Wilkerson April 21, 2025 Washington Correspondent ...